Hypnotic benzodiazepine receptor agonist exposure during pregnancy and the risk of congenital malformations and other adverse pregnancy outcomes: A systematic review and meta-analysis

Sophie Grigoriadis 1, Aseel Alibrahim 2, Joanna K Mansfield 1, Amanda Sullovey 1, Gail Erlick Robinson 1

Affiliations

01 October 2022

-

doi: 10.1111/acps.13441

Abstract

Objective: To determine if there is an association between antenatal hypnotic benzodiazepine receptor agonist exposure and congenital malformations or other adverse pregnancy outcomes in the offspring.

Methods: Databases were searched to January 31, 2021. Cohort studies published in English on congenital malformations or other adverse pregnancy outcomes in infants following exposure compared with those unexposed, were summarized and meta-analyzed where possible.

Results: Following screening, 25 studies were assessed for eligibility and seven included in the meta-analyses. Five studies were pooled for congenital malformations following first trimester exposure and not statistically significant (OR 0.87, 95% CI 0.56-1.36). The five studies that assessed for preterm birth following anytime exposure did pool to a statistically significant effect (OR 1.49, 95% CI 1.19-1.86); study quality, control for other psychotropic drugs and psychiatric diagnosis did not appear to be moderators. There were two missing studies when examining for publication bias in both of the main analyses above but the revised estimates were similar to the original. Low birth weight (LBW) was significant (three studies, any time exposure, OR 1.51, 1.27-1.78) as was small for gestational age (SGA) (three studies with anytime exposure, OR 1.34, 1.22-1.48). There were too few studies to summarize birth weight, gestational age, respiratory difficulties, APGAR score at 5 min and NICU admission.

Conclusions: Pregnancy exposure to hypnotics was not associated with a higher risk for congenital malformations but was associated with an increased risk for preterm birth, LBW and SGA compared with those infants who were not exposed. These findings are consistent with the antidepressant and benzodiazepine literature.

Keywords: HBRA; congenital malformations; delivery outcomes; hypnotic; pregnancy.

Similar articles

Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations.

Wikner BN, Stiller CO, Bergman U, Asker C, Källén B.Pharmacoepidemiol Drug Saf. 2007 Nov;16(11):1203-10. doi: 10.1002/pds.1457.PMID: 17894421

Pregnancy and Delivery Outcomes Following Benzodiazepine Exposure: A Systematic Review and Meta-analysis.

Grigoriadis S, Graves L, Peer M, Mamisashvili L, Ruthirakuhan M, Chan P, Hennawy M, Parikh S, Vigod SN, Dennis CL, Steiner M, Brown C, Cheung A, Dawson H, Rector N, Guenette M, Richter M.Can J Psychiatry. 2020 Dec;65(12):821-834. doi: 10.1177/0706743720904860. Epub 2020 Mar 9.PMID: 32148076 Free PMC article.

Gestational Exposure to Benzodiazepines and Z-Hypnotics and the Risk of Major Congenital Malformations, Ectopic Pregnancy, and Other Adverse Pregnancy Outcomes.

Andrade C.J Clin Psychiatry. 2023 Apr 3;84(2):23f14874. doi: 10.4088/JCP.23f14874.PMID: 37022751

Safety of topical corticosteroids in pregnancy.

Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C.Cochrane Database Syst Rev. 2015 Oct 26;2015(10):CD007346. doi: 10.1002/14651858.CD007346.pub3.PMID: 26497573 Free PMC article. Review.

Adverse pregnancy outcomes among mothers with hypertensive disorders in pregnancy: A meta-analysis of cohort studies.

Li F, Wang T, Chen L, Zhang S, Chen L, Qin J.Pregnancy Hypertens. 2021 Jun;24:107-117. doi: 10.1016/j.preghy.2021.03.001. Epub 2021 Mar 20.PMID: 33813363 Review.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Rossow I, Bramness JG. The total sale of prescription drugs with an abuse potential predicts the number of excessive users: a national prescription database study. BMC Publ Health. 2015;15(1):288.
  2.  
    1. Gunja N. The clinical and forensic toxicology of Z-drugs. J Med Toxicol. 2013;9(2):155-162.
  3.  
    1. Morin CM, Benca RM. Chapter 45 - Insomnia: nature, diagnosis, and treatment. In: Montagna P, Chokroverty S, eds. Handbook of Clinical Neurology. Vol 99. Elsevier; 2011:723-746.
  4.  
    1. Askaa B, Jimenez-Solem E, Enghusen Poulsen H, Traerup AJ. Maternal characteristics of women exposed to hypnotic benzodiazepine receptor agonist during pregnancy. Obstetr Gynecol Int. 2014;2014:1-5.
  5.  
    1. Okun ML, Ebert R, Saini B. A review of sleep-promoting medications used in pregnancy. Am J Obstetr Gynecol. 2015;212(4):428-441.
  6.  
    1. Huitfeldt A, Sundbakk LM, Skurtveit S, Handal M, Nordeng H. Associations of maternal use of benzodiazepines or benzodiazepine-like hypnotics during pregnancy with immediate pregnancy outcomes in Norway. JAMA Network Open. 2020;3(6):e205860.
  7.  
    1. Ban L, West J, Gibson JE, et al. First trimester exposure to anxiolytic and hypnotic drugs and the risks of major congenital anomalies: a United Kingdom population-based cohort study. PLoS ONE. 2014;9(6):e100996.
  8.  
    1. Juric S, Newport DJ, Ritchie JC, Galanti M, Stowe ZN. Zolpidem (Ambien®) in pregnancy: placental passage and outcome. Arch Women's Mental Health. 2009;12(6):441-446.
  9.  
    1. Grigoriadis S, Graves L, Peer M, et al. Benzodiazepine use during pregnancy alone or in combination with an antidepressant and congenital malformations: Systematic review and meta-analysis. J Clin Psychiatry. 2019;80(4). doi:10.4088/JCP.18r12412
  10.  
    1. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-2012.
  11.  
    1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
  12.  
    1. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Commun Health. 1998;52(6):377-384.
  13.  
    1. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
  14.  
    1. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Internal Med. 2007;147(8):573.
  15.  
    1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
  16.  
    1. Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558.
  17.  
    1. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455-463.
  18.  
    1. Wikner B, Källén B. Are hypnotic benzodiazepine receptor agonists teratogenic in humans? J Clin Psychopharmacol. 2011;31(3):356-359.
  19.  
    1. Wikner B, Stiller CO, Kallen B, Asker C. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: maternal characteristics. Pharmacoepidemiol Drug Saf. 2007;16(9):988-994.
  20.  
    1. Källén B, Reis M. Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy. J Clin Psychopharmacol. 2012;32(5):608-614.
  21.  
    1. Reis M, Kallen B. Combined use of selective serotonin reuptake inhibitors and sedatives/hypnotics during pregnancy: risk of relatively severe congenital malformations or cardiac defects. A register study. BMJ Open. 2013;3(2):e002166.
  22.  
    1. Källén B, Borg N, Reis M. The use of central nervous system active drugs during pregnancy. Pharmaceuticals. 2013;6(10):1221-1286.
  23.  
    1. Wang L, Lin H, Lin C, Chen Y, Lin H. Increased risk of adverse pregnancy outcomes in women receiving zolpidem during pregnancy. Clin Pharmacol Ther. 2010;88(3):369-374.
  24.  
    1. Diav-Citrin O, Okotore B, Lucarelli K, Koren G. Zopiclone use during pregnancy. Can Fam Phys. 2000;46:63-64.
  25.  
    1. Einarson A. The importance of critical evaluation of the literature regarding safety of antidepressant use in pregnancy. Acta Psychiatr Scand. 2013;127(2):115-116.
  26.  
    1. Fjalland BCJ, Grell S. GABA receptor stimulation increases the release of vasopressin and oxytocin in vitro. Eur J Pharmacol. 1987;142(1):155-158.
  27.  
    1. Baribeau DA, Anagnostou E. Oxytocin and vasopressin: linking pituitary neuropeptides and their receptors to social neurocircuits. Front Neurosci. 2015;9:335. doi:10.3389/fnins.2015.00335
  28.  
    1. Ambien. Highlights of prescribing information. Product Monograph. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019908s027lbl.pdf
  29.  
    1. Sedov I, Anderson N, Dhillon A, Tomfohr-Madsen L. Insomnia symptoms during pregnancy: a meta-analysis. J Sleep Res. 2021;30(1):e13207.
  30.  
    1. Vesga-López O, Blanco C, Keyes K, Olfson M, Grant BF, Hasin DS. Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry. 2008;65(7):805-815.
  31.  
    1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602.
  32.  
    1. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis. J Clin Psychiatry. 2013;74(4):321-341.
  33.  
    1. Grigoriadis S, Graves L, Peer M, et al. Maternal anxiety during pregnancy and the association with adverse perinatal outcomes: Systematic review and meta-analysis. J Clin Psychiatry. 2018;79(5). doi:10.4088/JCP.17r12011
  34.  
    1. Cripe SM, Frederick IO, Qiu C, Williams MA. Risk of preterm delivery and hypertensive disorders of pregnancy in relation to maternal co-morbid mood and migraine disorders during pregnancy. Paediatr Perin Epidemiol. 2011;25(2):116-123.
  35.  
    1. Istvan J. Stress, anxiety, and birth outcomes: a critical review of the evidence. Psychol Bull. 1986;100(3):331-348.
  36.  
    1. Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry. 2010;67(10):1012-1024.
  37.  
    1. Chen YH, Lin HC, Lee HC. Pregnancy outcomes among women with panic disorder - do panic attacks during pregnancy matter? J Affect Disord. 2010;120(1-3):258-262.
  38.  
    1. Ding X, Wu Y, Xu S, et al. Maternal anxiety during pregnancy and adverse birth outcomes: a systematic review and meta-analysis of prospective cohort studies. J Affect Disord. 2014;159:103-110.
  39.  
    1. Ross LE, McLean LM. Anxiety disorders during pregnancy and the postpartum period: a systematic review. J Clin Psychiatry. 2006;67(8):1285-1298.
  40.  
    1. Lu Q, Zhang X, Wang Y, et al. Sleep disturbances during pregnancy and adverse maternal and fetal outcomes: a systematic review and meta-analysis. Sleep Med Rev. 2021;58:101436.
  41.  
    1. Radojcic MR, El Marroun H, Miljkovic B, et al. Prenatal exposure to anxiolytic and hypnotic medication in relation to behavioral problems in childhood: a population-based cohort study. Neurotoxicol Teratol. 2017;61:58-65.

Page Navigation